H. Depenbrock

1.3k total citations · 1 hit paper
33 papers, 935 citations indexed

About

H. Depenbrock is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, H. Depenbrock has authored 33 papers receiving a total of 935 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in H. Depenbrock's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). H. Depenbrock is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). H. Depenbrock collaborates with scholars based in Germany, United States and United Kingdom. H. Depenbrock's co-authors include J. Blatter, A.-R. Hanauske, Axel‐R. Hanauske, R. Thödtmann, Rodryg Ramlau, Mark A. Socinski, Nick Thatcher, Alexander Luft, Beatrix Bálint and A. van Oosterom and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

H. Depenbrock

33 papers receiving 907 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by H. Depenbrock

Since Specialization

Citations

This map shows the geographic impact of H. Depenbrock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Depenbrock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Depenbrock more than expected).

Fields of papers citing papers by H. Depenbrock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Depenbrock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Depenbrock. The network helps show where H. Depenbrock may publish in the future.

Co-authorship network of co-authors of H. Depenbrock

This figure shows the co-authorship network connecting the top 25 collaborators of H. Depenbrock. A scholar is included among the top collaborators of H. Depenbrock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Depenbrock. H. Depenbrock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study 2017 ·Cancer Research and Treatment ·Keunchil Park, Eun Kyung Cho, (unknown), Myung‐Ju Ahn, Sumitra Thongprasert, Eun‐Kee Song, Victoria Soldatenkova, H. Depenbrock, Tarun Puri, Mauro Orlando	9
2	An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer 2017 ·Clinical Lung Cancer ·David R. Spigel, Alexander Luft, H. Depenbrock, Rodryg Ramlau, (unknown), Joo-Hang Kim, Carlos Mayo, (unknown), Coleman K. Obasaju, Ronald B. Natale	17
3	Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer 2017 ·Clinical Lung Cancer ·Tudor–Eliade Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Luft, Aleksandra Szczęsna, W Szafrański, Rodryg Ramlau, Beatrix Bálint, Olivier Molinier, H. Depenbrock, Shivani Nanda, Luis Paz‐Ares, Nick Thatcher	15
4	OA23.02 Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study 2017 ·Journal of Thoracic Oncology ·Tudor–Eliade Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Luft, Aleksandra Szczęsna, Rodryg Ramlau, Beatrix Bálint, Olivier Molinier, H. Depenbrock, Shivani Nanda, Luis Paz‐Ares, Nick Thatcher	1
5	Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE) 2016 ·Oncology Research and Treatment ·Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, J. Mezger, Mark A. Socinski, H. Depenbrock, Victoria Soldatenkova, Jacqueline Brown, (unknown), Nick Thatcher	9
6	Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study 2015 ·Journal of Thoracic Oncology ·Tudor–Eliade Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Luft, Aleksandra Szczęsna, W Szafrański, Rodryg Ramlau, Beatrix Bálint, Andrzej Każarnowicz, Olivier Molinier, H. Depenbrock, Shivani Nanda, Luis Paz‐Ares, Nick Thatcher	1
7	Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) 2015 ·Annals of Oncology ·N. Thatcher, T-E. Ciuleanu, Rodryg Ramlau, Christian Schumann, Luis Paz‐Ares, H. Depenbrock, Shivani Nanda, Nadia Chouaki, Mark A. Socinski	3
8	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Nick Thatcher, Fred R. Hirsch, Alexander Luft, Aleksandra Szczęsna, Tudor–Eliade Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy, Andrzej Każarnowicz, Keunchil Park, Christian Schumann, Martin Reck, H. Depenbrock, Shivani Nanda, (unknown), Raffael Kurek, Luis Paz‐Ares, Mark A. Socinski	331
9	Pemetrexed/gemcitabine/cisplatin: Phase I trial in patients with solid tumors 2004 ·Journal of Clinical Oncology ·Claus Bolling, (unknown), (unknown), (unknown), (unknown), (unknown), J. Blatter, H. Depenbrock, U. Ohnmacht, A.-R. Hanauske	4
10	In vitro activity of liposomal N4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells 2001 ·Investigational New Drugs ·Reto A. Schwendener, (unknown), H. Depenbrock, Herbert Schott, A.-R. Hanauske	13
11	Preclinical activity of 17β-[N-[N′-(2-chloroethyl)-N′-nitrosocarbamoyl]-l-alanyl]-5α-dihydrotestosterone (E91) against tumour colony forming units and haematopoietic progenitor cells 1999 ·European Journal of Cancer ·(unknown), Robert Peter, H. Depenbrock, Gerhard Eisenbrand, P. Schmid, (unknown), Axel‐R. Hanauske	8
12	Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells 1997 ·European Journal of Cancer ·H. Depenbrock, (unknown), Robert Peter, Bernhard K. Keppler, Gregor Weirich, Thomas Block, Johann Rastetter, A.-R. Hanauske	46
13	Efficacy of 5′-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro 1996 ·Investigational New Drugs ·(unknown), H. Depenbrock, Robert Peter, Thomas Block, (unknown), (unknown), Axel‐R. Hanauske	2
14	Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell linesin vitro 1995 ·Investigational New Drugs ·H. Depenbrock, Arash Shirvani, Johann Rastetter, Axel‐R. Hanauske	10
15	Characterization and mutual ligand-induced modulation of epidermal growth factor and interferon-α receptors on renal carcinoma cells in vitro 1995 ·Anti-Cancer Drugs ·(unknown), H. Depenbrock, Johann Rastetter, Axel‐R. Hanauske	4
16	Interleukin 1 modulates growth of human renal carcinoma cells in vitro 1995 ·British Journal of Cancer ·Ina Koch, H. Depenbrock, S. Danhauser-Riedl, (unknown), (unknown)	15
17	Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro 1995 ·European Journal of Cancer ·A.-R. Hanauske, (unknown), A. Lehmer, Michael C. Rotter, (unknown), (unknown), Johann Rastetter, H. Depenbrock	11
18	Effects of the microtubule-disturbing agents docetaxel (taxotere®), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro 1994 ·European Journal of Cancer ·A.-R. Hanauske, H. Depenbrock, (unknown), (unknown)	15
19	Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: Comparison with taxol and conventional antineoplastic agents 1993 ·European Journal of Cancer ·(unknown), Susan G. Hilsenbeck, H. Depenbrock, S. Danhauser-Riedl, Thomas Block, H. Nekarda, (unknown), Matti Aapro, Marie-Christine Bissery, Johann Rastetter, A.-R. Hanauske	40
20	Effects of cytokines on in vitro colony formation of primary human tumour specimens 1990 ·European Journal of Cancer and Clinical Oncology ·(unknown), H. Depenbrock, Mathias Freund, Georg Erdmann, H.-J. Meyer, Werner de Riese, (unknown), (unknown), (unknown), H. Poliwoda, A.-R. Hanauske	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact